NLS Pharmaceutics AG (NLSPW) - Net Assets
Based on the latest financial reports, NLS Pharmaceutics AG (NLSPW) has net assets worth $2.88 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($4.34 Million) and total liabilities ($1.46 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read NLS Pharmaceutics AG debt and liabilities for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.88 Million |
| % of Total Assets | 66.45% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 437.07 |
NLS Pharmaceutics AG - Net Assets Trend (2017–2024)
This chart illustrates how NLS Pharmaceutics AG's net assets have evolved over time, based on quarterly financial data. Also explore total assets of NLS Pharmaceutics AG for the complete picture of this company's asset base.
Annual Net Assets for NLS Pharmaceutics AG (2017–2024)
The table below shows the annual net assets of NLS Pharmaceutics AG from 2017 to 2024. For live valuation and market cap data, see NLS Pharmaceutics AG (NLSPW) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $1.41 Million | +115.92% |
| 2023-12-31 | $-8.83 Million | -369.25% |
| 2022-12-31 | $3.28 Million | +504.89% |
| 2021-12-31 | $542.39K | +106.04% |
| 2020-12-31 | $-8.98 Million | -45.59% |
| 2019-12-31 | $-6.17 Million | +29.98% |
| 2018-12-31 | $-8.81 Million | -14.20% |
| 2017-12-31 | $-7.72 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to NLS Pharmaceutics AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5812612300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $166.35K | 11.83% |
| Other Comprehensive Income | $108.85K | 7.74% |
| Other Components | $75.56 Million | 5372.85% |
| Total Equity | $1.41 Million | 100.00% |
NLS Pharmaceutics AG Competitors by Market Cap
The table below lists competitors of NLS Pharmaceutics AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Lucy Scientific Discovery Inc.
NASDAQ:LSDIF
|
$176.48 |
|
Ordinary Fully Paid Deferred Settlement
AU:ADDDB
|
$182.95 |
|
VIFRANA
RO:BIOW
|
$186.44 |
|
Carbon Revolution Public Limited Ordinary Shares
NASDAQ:CREV
|
$192.78 |
|
Seed Capital Solutions Plc
LSE:SCSP
|
$169.19 |
|
Future Lifestyle Fashions Limited
NSE:FLFL
|
$152.00 |
|
Adheris Health Limited
AU:AHE
|
$137.04 |
|
PetroFrontier Corp
V:PFC
|
$131.55 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NLS Pharmaceutics AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -8,833,563 to 1,406,361, a change of 10,239,924.
- Net loss of 1,980,810 reduced equity.
- New share issuances of 5,252,725 increased equity.
- Other comprehensive income increased equity by 266,924.
- Other factors increased equity by 6,701,085.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.98 Million | -140.85% |
| Share Issuances | $5.25 Million | +373.5% |
| Other Comprehensive Income | $266.92K | +18.98% |
| Other Changes | $6.70 Million | +476.48% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares NLS Pharmaceutics AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-6.55 | $0.02 | x |
| 2018-12-31 | $-550856.81 | $0.02 | x |
| 2019-12-31 | $-5.54 | $0.02 | x |
| 2020-12-31 | $-18.64 | $0.02 | x |
| 2021-12-31 | $0.04 | $0.02 | x |
| 2022-12-31 | $1.67 | $0.02 | x |
| 2023-12-31 | $-2.31 | $0.02 | x |
| 2024-12-31 | $9.11 | $0.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NLS Pharmaceutics AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -140.85%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.59x
- Recent ROE (-140.85%) is above the historical average (-355.77%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.89 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.27 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.83 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.96 Million |
| 2021 | -2202.50% | 0.00% | 0.00x | 10.63x | $-12.00 Million |
| 2022 | -502.79% | 0.00% | 0.00x | 2.83x | $-16.82 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-11.29 Million |
| 2024 | -140.85% | 0.00% | 0.00x | 1.59x | $-2.12 Million |
Industry Comparison
This section compares NLS Pharmaceutics AG's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $173,740,057
- Average return on equity (ROE) among peers: -43.94%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NLS Pharmaceutics AG (NLSPW) | $2.88 Million | 0.00% | 0.50x | $169.32 |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.69 Million | 20.23% | 0.26x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $70.43 Million | -172.28% | 0.74x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $448.19K |
| Absci Corp (ABSI) | $-41.16 Million | 0.00% | 0.00x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $38.29 Million | -30.60% | 0.11x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $60.67K | -43.96% | 0.04x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $25.93 Million | -163.70% | 3.21x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $699.13 Million | -33.65% | 0.12x | $3.74 Billion |
About NLS Pharmaceutics AG
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity … Read more